CSL offshoot Seqirus has announced the launch of its first Schedule 2 (OTC) product Nervoderm, a dual-action medicated patch containing lidocaine, "clinically proven to relieve nerve pain associated with medically diagnosed post-herpetic neuralgia (PHN)".
Nervoderm has been launched in partnership with Pharmabroker Sales - see nervoderm.com.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 04 Oct 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 04 Oct 17